Keryx Biopharmaceuticals Announces Completion of Interim Analysis by Data Safety Monitoring Board for the Phase 3 Study of KRX-0401 for the Treatment of Refractory Advanced Colorectal Cancer

Keryx Biopharmaceuticals, Inc. KERX announced today that the independent Data Safety Monitoring Board (DSMB) for the Company's pivotal Phase 3 X-PECT study of KRX-0401 (perifosine) in patients with refractory advanced colorectal cancer has completed a pre-specified interim analysis for safety and futility. The independent DSMB has recommended that the Phase 3 study continue to completion, as planned. This Phase 3 study has completed enrollment, with over 465 patients from 65 U.S. sites, and is being conducted pursuant to a Special Protocol Assessment with the Food and Drug Administration and with Fast-Track Designation.